myriocin Search Results


myriocin  (MedChemExpress)
94
MedChemExpress myriocin
<t>SPT</t> inhibition represses cocaine-induced neurobehaviors and sphingolipid metabolism reprogramming in the NAc. (A) Upper: diagram of establishing cocaine-induced hyperlocomotor activity in mice with <t>myriocin</t> pretreatment. Lower: total distances of mice travelled before or after i.p. injection of 20 mg/kg cocaine with myriocin pretreatment (0.3, 1 mg/kg) and the vehicle control (n = 10). Mice received vehicle or myriocin 30 min before daily behavioral testing. (B) Bar graph shows the changes of SPT activity measured by ELISA assay in mice pretreated with myriocin (1 mg/kg) (n = 6). Main effects: cocaine, F (1,20) = 9.455, p = 0.006; myriocin, F (1,20) = 28.21, p < 0.0001; interaction, F (1,20) = 28.58, p < 0.0001. (C,D) Bar graph shows the levels of 3-ketosphinganine (C) and dihydrosphinganine (D) in the NAc of cocaine-treated mice with myriocin (1 mg/kg) pretreatment (n = 4). 3-ketosphinganine, main effects: cocaine, F (1,12) = 9.455, p = 0.006; myriocin, F (1,12) = 28.21, p < 0.0001; interaction, F (1,12) = 28.58, p < 0.0001. Dihydrosphinganine, main effects: cocaine, F (1,12) = 12.73, p = 0.0039; myriocin, F (1,12) = 5.8529, p = 0.0327; interaction, F (1,12) = 4.175, p = 0.0636. (E) The dot matrix chart shows eight minor categories of sphingolipids significantly changed by myriocin (1 mg/kg) pretreatment in cocaine-treated group. The color of the dots represents a lipid subclass and the quantity of the dots represents the percentage. (F) Bar graph shows the intensity of a series of changed sphingolipids in the NAc of mice with cocaine-induced hyperlocomotion (n = 10). (G) Diagram of establishing cocaine CPP model. Bar graph shows the cocaine CPP scores with myriocin pretreatment and the vehicle control (0.3, 1 mg/kg) (n = 8). (H,I) Bar graph shows the levels of 3-ketosphinganine (H) and dihydrosphinganine (I) in the NAc of cocaine CPP mice with myriocin (1 mg/kg) pretreatment (n = 4). 3-ketosphinganine, main effects: cocaine, F (1,12) = 11.57, p = 0.0052; myriocin, F (1,12) = 15.43, p = 0.0020; interaction, F (1,12) = 6.280, p = 0.0276; Dihydrosphinganine, main effects: cocaine, F (1,12) = 1.456, p = 0.2508; myriocin, F (1,12) = 0.0949, p = 0.7633; interaction, F (1,12) = 5.285, p = 0.0403. (J) The dot matrix chart shows eight minor categories of sphingolipids significantly modified by myriocin (1 mg/kg) of cocaine-treated mice. (K) Bar graph shows the intensity of a series of changed sphingolipids in the NAc of cocaine CPP mice with myriocin (1 mg/kg) pretreatment (n = 10). Data are presented as mean ± SEM and analyzed using two-way ANOVA followed by Turkey’s multiple comparisons test. * p < 0.05; ** p < 0.01; *** p < 0.01; **** p < 0.0001 vs. saline group. # p < 0.05. ## p < 0.01; ### p < 0.001 vs. cocaine group; ns, p > 0.05.
Myriocin, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/myriocin/Myriocin/pmc12685851-49-3-5
Average 94 stars, based on 1 article reviews
myriocin - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier
myriocin myr  (Santa Cruz Biotechnology)
93
Santa Cruz Biotechnology myriocin myr
<t>SPT</t> inhibition represses cocaine-induced neurobehaviors and sphingolipid metabolism reprogramming in the NAc. (A) Upper: diagram of establishing cocaine-induced hyperlocomotor activity in mice with <t>myriocin</t> pretreatment. Lower: total distances of mice travelled before or after i.p. injection of 20 mg/kg cocaine with myriocin pretreatment (0.3, 1 mg/kg) and the vehicle control (n = 10). Mice received vehicle or myriocin 30 min before daily behavioral testing. (B) Bar graph shows the changes of SPT activity measured by ELISA assay in mice pretreated with myriocin (1 mg/kg) (n = 6). Main effects: cocaine, F (1,20) = 9.455, p = 0.006; myriocin, F (1,20) = 28.21, p < 0.0001; interaction, F (1,20) = 28.58, p < 0.0001. (C,D) Bar graph shows the levels of 3-ketosphinganine (C) and dihydrosphinganine (D) in the NAc of cocaine-treated mice with myriocin (1 mg/kg) pretreatment (n = 4). 3-ketosphinganine, main effects: cocaine, F (1,12) = 9.455, p = 0.006; myriocin, F (1,12) = 28.21, p < 0.0001; interaction, F (1,12) = 28.58, p < 0.0001. Dihydrosphinganine, main effects: cocaine, F (1,12) = 12.73, p = 0.0039; myriocin, F (1,12) = 5.8529, p = 0.0327; interaction, F (1,12) = 4.175, p = 0.0636. (E) The dot matrix chart shows eight minor categories of sphingolipids significantly changed by myriocin (1 mg/kg) pretreatment in cocaine-treated group. The color of the dots represents a lipid subclass and the quantity of the dots represents the percentage. (F) Bar graph shows the intensity of a series of changed sphingolipids in the NAc of mice with cocaine-induced hyperlocomotion (n = 10). (G) Diagram of establishing cocaine CPP model. Bar graph shows the cocaine CPP scores with myriocin pretreatment and the vehicle control (0.3, 1 mg/kg) (n = 8). (H,I) Bar graph shows the levels of 3-ketosphinganine (H) and dihydrosphinganine (I) in the NAc of cocaine CPP mice with myriocin (1 mg/kg) pretreatment (n = 4). 3-ketosphinganine, main effects: cocaine, F (1,12) = 11.57, p = 0.0052; myriocin, F (1,12) = 15.43, p = 0.0020; interaction, F (1,12) = 6.280, p = 0.0276; Dihydrosphinganine, main effects: cocaine, F (1,12) = 1.456, p = 0.2508; myriocin, F (1,12) = 0.0949, p = 0.7633; interaction, F (1,12) = 5.285, p = 0.0403. (J) The dot matrix chart shows eight minor categories of sphingolipids significantly modified by myriocin (1 mg/kg) of cocaine-treated mice. (K) Bar graph shows the intensity of a series of changed sphingolipids in the NAc of cocaine CPP mice with myriocin (1 mg/kg) pretreatment (n = 10). Data are presented as mean ± SEM and analyzed using two-way ANOVA followed by Turkey’s multiple comparisons test. * p < 0.05; ** p < 0.01; *** p < 0.01; **** p < 0.0001 vs. saline group. # p < 0.05. ## p < 0.01; ### p < 0.001 vs. cocaine group; ns, p > 0.05.
Myriocin Myr, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/myriocin/Myriocin/pm33414455-54-3-23
Average 93 stars, based on 1 article reviews
myriocin myr - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier
myriocin  (LKT Laboratories)
90
LKT Laboratories myriocin
<t>SPT</t> inhibition represses cocaine-induced neurobehaviors and sphingolipid metabolism reprogramming in the NAc. (A) Upper: diagram of establishing cocaine-induced hyperlocomotor activity in mice with <t>myriocin</t> pretreatment. Lower: total distances of mice travelled before or after i.p. injection of 20 mg/kg cocaine with myriocin pretreatment (0.3, 1 mg/kg) and the vehicle control (n = 10). Mice received vehicle or myriocin 30 min before daily behavioral testing. (B) Bar graph shows the changes of SPT activity measured by ELISA assay in mice pretreated with myriocin (1 mg/kg) (n = 6). Main effects: cocaine, F (1,20) = 9.455, p = 0.006; myriocin, F (1,20) = 28.21, p < 0.0001; interaction, F (1,20) = 28.58, p < 0.0001. (C,D) Bar graph shows the levels of 3-ketosphinganine (C) and dihydrosphinganine (D) in the NAc of cocaine-treated mice with myriocin (1 mg/kg) pretreatment (n = 4). 3-ketosphinganine, main effects: cocaine, F (1,12) = 9.455, p = 0.006; myriocin, F (1,12) = 28.21, p < 0.0001; interaction, F (1,12) = 28.58, p < 0.0001. Dihydrosphinganine, main effects: cocaine, F (1,12) = 12.73, p = 0.0039; myriocin, F (1,12) = 5.8529, p = 0.0327; interaction, F (1,12) = 4.175, p = 0.0636. (E) The dot matrix chart shows eight minor categories of sphingolipids significantly changed by myriocin (1 mg/kg) pretreatment in cocaine-treated group. The color of the dots represents a lipid subclass and the quantity of the dots represents the percentage. (F) Bar graph shows the intensity of a series of changed sphingolipids in the NAc of mice with cocaine-induced hyperlocomotion (n = 10). (G) Diagram of establishing cocaine CPP model. Bar graph shows the cocaine CPP scores with myriocin pretreatment and the vehicle control (0.3, 1 mg/kg) (n = 8). (H,I) Bar graph shows the levels of 3-ketosphinganine (H) and dihydrosphinganine (I) in the NAc of cocaine CPP mice with myriocin (1 mg/kg) pretreatment (n = 4). 3-ketosphinganine, main effects: cocaine, F (1,12) = 11.57, p = 0.0052; myriocin, F (1,12) = 15.43, p = 0.0020; interaction, F (1,12) = 6.280, p = 0.0276; Dihydrosphinganine, main effects: cocaine, F (1,12) = 1.456, p = 0.2508; myriocin, F (1,12) = 0.0949, p = 0.7633; interaction, F (1,12) = 5.285, p = 0.0403. (J) The dot matrix chart shows eight minor categories of sphingolipids significantly modified by myriocin (1 mg/kg) of cocaine-treated mice. (K) Bar graph shows the intensity of a series of changed sphingolipids in the NAc of cocaine CPP mice with myriocin (1 mg/kg) pretreatment (n = 10). Data are presented as mean ± SEM and analyzed using two-way ANOVA followed by Turkey’s multiple comparisons test. * p < 0.05; ** p < 0.01; *** p < 0.01; **** p < 0.0001 vs. saline group. # p < 0.05. ## p < 0.01; ### p < 0.001 vs. cocaine group; ns, p > 0.05.
Myriocin, supplied by LKT Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/myriocin/Myriocin/10__1128_slash_mbio__01467___19-321-3-4
Average 90 stars, based on 1 article reviews
myriocin - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
isp-1  (Biomol GmbH)
90
Biomol GmbH isp-1
<t>SPT</t> inhibition represses cocaine-induced neurobehaviors and sphingolipid metabolism reprogramming in the NAc. (A) Upper: diagram of establishing cocaine-induced hyperlocomotor activity in mice with <t>myriocin</t> pretreatment. Lower: total distances of mice travelled before or after i.p. injection of 20 mg/kg cocaine with myriocin pretreatment (0.3, 1 mg/kg) and the vehicle control (n = 10). Mice received vehicle or myriocin 30 min before daily behavioral testing. (B) Bar graph shows the changes of SPT activity measured by ELISA assay in mice pretreated with myriocin (1 mg/kg) (n = 6). Main effects: cocaine, F (1,20) = 9.455, p = 0.006; myriocin, F (1,20) = 28.21, p < 0.0001; interaction, F (1,20) = 28.58, p < 0.0001. (C,D) Bar graph shows the levels of 3-ketosphinganine (C) and dihydrosphinganine (D) in the NAc of cocaine-treated mice with myriocin (1 mg/kg) pretreatment (n = 4). 3-ketosphinganine, main effects: cocaine, F (1,12) = 9.455, p = 0.006; myriocin, F (1,12) = 28.21, p < 0.0001; interaction, F (1,12) = 28.58, p < 0.0001. Dihydrosphinganine, main effects: cocaine, F (1,12) = 12.73, p = 0.0039; myriocin, F (1,12) = 5.8529, p = 0.0327; interaction, F (1,12) = 4.175, p = 0.0636. (E) The dot matrix chart shows eight minor categories of sphingolipids significantly changed by myriocin (1 mg/kg) pretreatment in cocaine-treated group. The color of the dots represents a lipid subclass and the quantity of the dots represents the percentage. (F) Bar graph shows the intensity of a series of changed sphingolipids in the NAc of mice with cocaine-induced hyperlocomotion (n = 10). (G) Diagram of establishing cocaine CPP model. Bar graph shows the cocaine CPP scores with myriocin pretreatment and the vehicle control (0.3, 1 mg/kg) (n = 8). (H,I) Bar graph shows the levels of 3-ketosphinganine (H) and dihydrosphinganine (I) in the NAc of cocaine CPP mice with myriocin (1 mg/kg) pretreatment (n = 4). 3-ketosphinganine, main effects: cocaine, F (1,12) = 11.57, p = 0.0052; myriocin, F (1,12) = 15.43, p = 0.0020; interaction, F (1,12) = 6.280, p = 0.0276; Dihydrosphinganine, main effects: cocaine, F (1,12) = 1.456, p = 0.2508; myriocin, F (1,12) = 0.0949, p = 0.7633; interaction, F (1,12) = 5.285, p = 0.0403. (J) The dot matrix chart shows eight minor categories of sphingolipids significantly modified by myriocin (1 mg/kg) of cocaine-treated mice. (K) Bar graph shows the intensity of a series of changed sphingolipids in the NAc of cocaine CPP mice with myriocin (1 mg/kg) pretreatment (n = 10). Data are presented as mean ± SEM and analyzed using two-way ANOVA followed by Turkey’s multiple comparisons test. * p < 0.05; ** p < 0.01; *** p < 0.01; **** p < 0.0001 vs. saline group. # p < 0.05. ## p < 0.01; ### p < 0.001 vs. cocaine group; ns, p > 0.05.
Isp 1, supplied by Biomol GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/myriocin/spt+inhibitor+myriocin/pmc03791605-65-0-3
Average 90 stars, based on 1 article reviews
isp-1 - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
myriocin  (ApexBio)
90
ApexBio myriocin
<t>SPT</t> inhibition represses cocaine-induced neurobehaviors and sphingolipid metabolism reprogramming in the NAc. (A) Upper: diagram of establishing cocaine-induced hyperlocomotor activity in mice with <t>myriocin</t> pretreatment. Lower: total distances of mice travelled before or after i.p. injection of 20 mg/kg cocaine with myriocin pretreatment (0.3, 1 mg/kg) and the vehicle control (n = 10). Mice received vehicle or myriocin 30 min before daily behavioral testing. (B) Bar graph shows the changes of SPT activity measured by ELISA assay in mice pretreated with myriocin (1 mg/kg) (n = 6). Main effects: cocaine, F (1,20) = 9.455, p = 0.006; myriocin, F (1,20) = 28.21, p < 0.0001; interaction, F (1,20) = 28.58, p < 0.0001. (C,D) Bar graph shows the levels of 3-ketosphinganine (C) and dihydrosphinganine (D) in the NAc of cocaine-treated mice with myriocin (1 mg/kg) pretreatment (n = 4). 3-ketosphinganine, main effects: cocaine, F (1,12) = 9.455, p = 0.006; myriocin, F (1,12) = 28.21, p < 0.0001; interaction, F (1,12) = 28.58, p < 0.0001. Dihydrosphinganine, main effects: cocaine, F (1,12) = 12.73, p = 0.0039; myriocin, F (1,12) = 5.8529, p = 0.0327; interaction, F (1,12) = 4.175, p = 0.0636. (E) The dot matrix chart shows eight minor categories of sphingolipids significantly changed by myriocin (1 mg/kg) pretreatment in cocaine-treated group. The color of the dots represents a lipid subclass and the quantity of the dots represents the percentage. (F) Bar graph shows the intensity of a series of changed sphingolipids in the NAc of mice with cocaine-induced hyperlocomotion (n = 10). (G) Diagram of establishing cocaine CPP model. Bar graph shows the cocaine CPP scores with myriocin pretreatment and the vehicle control (0.3, 1 mg/kg) (n = 8). (H,I) Bar graph shows the levels of 3-ketosphinganine (H) and dihydrosphinganine (I) in the NAc of cocaine CPP mice with myriocin (1 mg/kg) pretreatment (n = 4). 3-ketosphinganine, main effects: cocaine, F (1,12) = 11.57, p = 0.0052; myriocin, F (1,12) = 15.43, p = 0.0020; interaction, F (1,12) = 6.280, p = 0.0276; Dihydrosphinganine, main effects: cocaine, F (1,12) = 1.456, p = 0.2508; myriocin, F (1,12) = 0.0949, p = 0.7633; interaction, F (1,12) = 5.285, p = 0.0403. (J) The dot matrix chart shows eight minor categories of sphingolipids significantly modified by myriocin (1 mg/kg) of cocaine-treated mice. (K) Bar graph shows the intensity of a series of changed sphingolipids in the NAc of cocaine CPP mice with myriocin (1 mg/kg) pretreatment (n = 10). Data are presented as mean ± SEM and analyzed using two-way ANOVA followed by Turkey’s multiple comparisons test. * p < 0.05; ** p < 0.01; *** p < 0.01; **** p < 0.0001 vs. saline group. # p < 0.05. ## p < 0.01; ### p < 0.001 vs. cocaine group; ns, p > 0.05.
Myriocin, supplied by ApexBio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/myriocin/myriocin/pm35211530-106-0-3
Average 90 stars, based on 1 article reviews
myriocin - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
myriocin  (GlpBio Technology Inc)
90
GlpBio Technology Inc myriocin
<t>SPT</t> inhibition represses cocaine-induced neurobehaviors and sphingolipid metabolism reprogramming in the NAc. (A) Upper: diagram of establishing cocaine-induced hyperlocomotor activity in mice with <t>myriocin</t> pretreatment. Lower: total distances of mice travelled before or after i.p. injection of 20 mg/kg cocaine with myriocin pretreatment (0.3, 1 mg/kg) and the vehicle control (n = 10). Mice received vehicle or myriocin 30 min before daily behavioral testing. (B) Bar graph shows the changes of SPT activity measured by ELISA assay in mice pretreated with myriocin (1 mg/kg) (n = 6). Main effects: cocaine, F (1,20) = 9.455, p = 0.006; myriocin, F (1,20) = 28.21, p < 0.0001; interaction, F (1,20) = 28.58, p < 0.0001. (C,D) Bar graph shows the levels of 3-ketosphinganine (C) and dihydrosphinganine (D) in the NAc of cocaine-treated mice with myriocin (1 mg/kg) pretreatment (n = 4). 3-ketosphinganine, main effects: cocaine, F (1,12) = 9.455, p = 0.006; myriocin, F (1,12) = 28.21, p < 0.0001; interaction, F (1,12) = 28.58, p < 0.0001. Dihydrosphinganine, main effects: cocaine, F (1,12) = 12.73, p = 0.0039; myriocin, F (1,12) = 5.8529, p = 0.0327; interaction, F (1,12) = 4.175, p = 0.0636. (E) The dot matrix chart shows eight minor categories of sphingolipids significantly changed by myriocin (1 mg/kg) pretreatment in cocaine-treated group. The color of the dots represents a lipid subclass and the quantity of the dots represents the percentage. (F) Bar graph shows the intensity of a series of changed sphingolipids in the NAc of mice with cocaine-induced hyperlocomotion (n = 10). (G) Diagram of establishing cocaine CPP model. Bar graph shows the cocaine CPP scores with myriocin pretreatment and the vehicle control (0.3, 1 mg/kg) (n = 8). (H,I) Bar graph shows the levels of 3-ketosphinganine (H) and dihydrosphinganine (I) in the NAc of cocaine CPP mice with myriocin (1 mg/kg) pretreatment (n = 4). 3-ketosphinganine, main effects: cocaine, F (1,12) = 11.57, p = 0.0052; myriocin, F (1,12) = 15.43, p = 0.0020; interaction, F (1,12) = 6.280, p = 0.0276; Dihydrosphinganine, main effects: cocaine, F (1,12) = 1.456, p = 0.2508; myriocin, F (1,12) = 0.0949, p = 0.7633; interaction, F (1,12) = 5.285, p = 0.0403. (J) The dot matrix chart shows eight minor categories of sphingolipids significantly modified by myriocin (1 mg/kg) of cocaine-treated mice. (K) Bar graph shows the intensity of a series of changed sphingolipids in the NAc of cocaine CPP mice with myriocin (1 mg/kg) pretreatment (n = 10). Data are presented as mean ± SEM and analyzed using two-way ANOVA followed by Turkey’s multiple comparisons test. * p < 0.05; ** p < 0.01; *** p < 0.01; **** p < 0.0001 vs. saline group. # p < 0.05. ## p < 0.01; ### p < 0.001 vs. cocaine group; ns, p > 0.05.
Myriocin, supplied by GlpBio Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/myriocin/myriocin/pmc11019908-120-0-58
Average 90 stars, based on 1 article reviews
myriocin - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
myriocin  (Biomol GmbH)
90
Biomol GmbH myriocin
<t>SPT</t> inhibition represses cocaine-induced neurobehaviors and sphingolipid metabolism reprogramming in the NAc. (A) Upper: diagram of establishing cocaine-induced hyperlocomotor activity in mice with <t>myriocin</t> pretreatment. Lower: total distances of mice travelled before or after i.p. injection of 20 mg/kg cocaine with myriocin pretreatment (0.3, 1 mg/kg) and the vehicle control (n = 10). Mice received vehicle or myriocin 30 min before daily behavioral testing. (B) Bar graph shows the changes of SPT activity measured by ELISA assay in mice pretreated with myriocin (1 mg/kg) (n = 6). Main effects: cocaine, F (1,20) = 9.455, p = 0.006; myriocin, F (1,20) = 28.21, p < 0.0001; interaction, F (1,20) = 28.58, p < 0.0001. (C,D) Bar graph shows the levels of 3-ketosphinganine (C) and dihydrosphinganine (D) in the NAc of cocaine-treated mice with myriocin (1 mg/kg) pretreatment (n = 4). 3-ketosphinganine, main effects: cocaine, F (1,12) = 9.455, p = 0.006; myriocin, F (1,12) = 28.21, p < 0.0001; interaction, F (1,12) = 28.58, p < 0.0001. Dihydrosphinganine, main effects: cocaine, F (1,12) = 12.73, p = 0.0039; myriocin, F (1,12) = 5.8529, p = 0.0327; interaction, F (1,12) = 4.175, p = 0.0636. (E) The dot matrix chart shows eight minor categories of sphingolipids significantly changed by myriocin (1 mg/kg) pretreatment in cocaine-treated group. The color of the dots represents a lipid subclass and the quantity of the dots represents the percentage. (F) Bar graph shows the intensity of a series of changed sphingolipids in the NAc of mice with cocaine-induced hyperlocomotion (n = 10). (G) Diagram of establishing cocaine CPP model. Bar graph shows the cocaine CPP scores with myriocin pretreatment and the vehicle control (0.3, 1 mg/kg) (n = 8). (H,I) Bar graph shows the levels of 3-ketosphinganine (H) and dihydrosphinganine (I) in the NAc of cocaine CPP mice with myriocin (1 mg/kg) pretreatment (n = 4). 3-ketosphinganine, main effects: cocaine, F (1,12) = 11.57, p = 0.0052; myriocin, F (1,12) = 15.43, p = 0.0020; interaction, F (1,12) = 6.280, p = 0.0276; Dihydrosphinganine, main effects: cocaine, F (1,12) = 1.456, p = 0.2508; myriocin, F (1,12) = 0.0949, p = 0.7633; interaction, F (1,12) = 5.285, p = 0.0403. (J) The dot matrix chart shows eight minor categories of sphingolipids significantly modified by myriocin (1 mg/kg) of cocaine-treated mice. (K) Bar graph shows the intensity of a series of changed sphingolipids in the NAc of cocaine CPP mice with myriocin (1 mg/kg) pretreatment (n = 10). Data are presented as mean ± SEM and analyzed using two-way ANOVA followed by Turkey’s multiple comparisons test. * p < 0.05; ** p < 0.01; *** p < 0.01; **** p < 0.0001 vs. saline group. # p < 0.05. ## p < 0.01; ### p < 0.001 vs. cocaine group; ns, p > 0.05.
Myriocin, supplied by Biomol GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/myriocin/myriocin/pmc02757191-83-11-12
Average 90 stars, based on 1 article reviews
myriocin - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
myriocin, a serine palmitoyltransferase inhibitor of the de novo ceramide synthesis pathway  (Biomol GmbH)
90
Biomol GmbH myriocin, a serine palmitoyltransferase inhibitor of the de novo ceramide synthesis pathway
<t>SPT</t> inhibition represses cocaine-induced neurobehaviors and sphingolipid metabolism reprogramming in the NAc. (A) Upper: diagram of establishing cocaine-induced hyperlocomotor activity in mice with <t>myriocin</t> pretreatment. Lower: total distances of mice travelled before or after i.p. injection of 20 mg/kg cocaine with myriocin pretreatment (0.3, 1 mg/kg) and the vehicle control (n = 10). Mice received vehicle or myriocin 30 min before daily behavioral testing. (B) Bar graph shows the changes of SPT activity measured by ELISA assay in mice pretreated with myriocin (1 mg/kg) (n = 6). Main effects: cocaine, F (1,20) = 9.455, p = 0.006; myriocin, F (1,20) = 28.21, p < 0.0001; interaction, F (1,20) = 28.58, p < 0.0001. (C,D) Bar graph shows the levels of 3-ketosphinganine (C) and dihydrosphinganine (D) in the NAc of cocaine-treated mice with myriocin (1 mg/kg) pretreatment (n = 4). 3-ketosphinganine, main effects: cocaine, F (1,12) = 9.455, p = 0.006; myriocin, F (1,12) = 28.21, p < 0.0001; interaction, F (1,12) = 28.58, p < 0.0001. Dihydrosphinganine, main effects: cocaine, F (1,12) = 12.73, p = 0.0039; myriocin, F (1,12) = 5.8529, p = 0.0327; interaction, F (1,12) = 4.175, p = 0.0636. (E) The dot matrix chart shows eight minor categories of sphingolipids significantly changed by myriocin (1 mg/kg) pretreatment in cocaine-treated group. The color of the dots represents a lipid subclass and the quantity of the dots represents the percentage. (F) Bar graph shows the intensity of a series of changed sphingolipids in the NAc of mice with cocaine-induced hyperlocomotion (n = 10). (G) Diagram of establishing cocaine CPP model. Bar graph shows the cocaine CPP scores with myriocin pretreatment and the vehicle control (0.3, 1 mg/kg) (n = 8). (H,I) Bar graph shows the levels of 3-ketosphinganine (H) and dihydrosphinganine (I) in the NAc of cocaine CPP mice with myriocin (1 mg/kg) pretreatment (n = 4). 3-ketosphinganine, main effects: cocaine, F (1,12) = 11.57, p = 0.0052; myriocin, F (1,12) = 15.43, p = 0.0020; interaction, F (1,12) = 6.280, p = 0.0276; Dihydrosphinganine, main effects: cocaine, F (1,12) = 1.456, p = 0.2508; myriocin, F (1,12) = 0.0949, p = 0.7633; interaction, F (1,12) = 5.285, p = 0.0403. (J) The dot matrix chart shows eight minor categories of sphingolipids significantly modified by myriocin (1 mg/kg) of cocaine-treated mice. (K) Bar graph shows the intensity of a series of changed sphingolipids in the NAc of cocaine CPP mice with myriocin (1 mg/kg) pretreatment (n = 10). Data are presented as mean ± SEM and analyzed using two-way ANOVA followed by Turkey’s multiple comparisons test. * p < 0.05; ** p < 0.01; *** p < 0.01; **** p < 0.0001 vs. saline group. # p < 0.05. ## p < 0.01; ### p < 0.001 vs. cocaine group; ns, p > 0.05.
Myriocin, A Serine Palmitoyltransferase Inhibitor Of The De Novo Ceramide Synthesis Pathway, supplied by Biomol GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/myriocin/myriocin++a+serine+palmitoyltransferase+inhibitor+of+the+de+novo+ceramide+synthesis+pathway/pmc02976739-16-0-15
Average 90 stars, based on 1 article reviews
myriocin, a serine palmitoyltransferase inhibitor of the de novo ceramide synthesis pathway - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
inhibitor of ceramide synthase myriocin  (Biomol GmbH)
90
Biomol GmbH inhibitor of ceramide synthase myriocin
<t>SPT</t> inhibition represses cocaine-induced neurobehaviors and sphingolipid metabolism reprogramming in the NAc. (A) Upper: diagram of establishing cocaine-induced hyperlocomotor activity in mice with <t>myriocin</t> pretreatment. Lower: total distances of mice travelled before or after i.p. injection of 20 mg/kg cocaine with myriocin pretreatment (0.3, 1 mg/kg) and the vehicle control (n = 10). Mice received vehicle or myriocin 30 min before daily behavioral testing. (B) Bar graph shows the changes of SPT activity measured by ELISA assay in mice pretreated with myriocin (1 mg/kg) (n = 6). Main effects: cocaine, F (1,20) = 9.455, p = 0.006; myriocin, F (1,20) = 28.21, p < 0.0001; interaction, F (1,20) = 28.58, p < 0.0001. (C,D) Bar graph shows the levels of 3-ketosphinganine (C) and dihydrosphinganine (D) in the NAc of cocaine-treated mice with myriocin (1 mg/kg) pretreatment (n = 4). 3-ketosphinganine, main effects: cocaine, F (1,12) = 9.455, p = 0.006; myriocin, F (1,12) = 28.21, p < 0.0001; interaction, F (1,12) = 28.58, p < 0.0001. Dihydrosphinganine, main effects: cocaine, F (1,12) = 12.73, p = 0.0039; myriocin, F (1,12) = 5.8529, p = 0.0327; interaction, F (1,12) = 4.175, p = 0.0636. (E) The dot matrix chart shows eight minor categories of sphingolipids significantly changed by myriocin (1 mg/kg) pretreatment in cocaine-treated group. The color of the dots represents a lipid subclass and the quantity of the dots represents the percentage. (F) Bar graph shows the intensity of a series of changed sphingolipids in the NAc of mice with cocaine-induced hyperlocomotion (n = 10). (G) Diagram of establishing cocaine CPP model. Bar graph shows the cocaine CPP scores with myriocin pretreatment and the vehicle control (0.3, 1 mg/kg) (n = 8). (H,I) Bar graph shows the levels of 3-ketosphinganine (H) and dihydrosphinganine (I) in the NAc of cocaine CPP mice with myriocin (1 mg/kg) pretreatment (n = 4). 3-ketosphinganine, main effects: cocaine, F (1,12) = 11.57, p = 0.0052; myriocin, F (1,12) = 15.43, p = 0.0020; interaction, F (1,12) = 6.280, p = 0.0276; Dihydrosphinganine, main effects: cocaine, F (1,12) = 1.456, p = 0.2508; myriocin, F (1,12) = 0.0949, p = 0.7633; interaction, F (1,12) = 5.285, p = 0.0403. (J) The dot matrix chart shows eight minor categories of sphingolipids significantly modified by myriocin (1 mg/kg) of cocaine-treated mice. (K) Bar graph shows the intensity of a series of changed sphingolipids in the NAc of cocaine CPP mice with myriocin (1 mg/kg) pretreatment (n = 10). Data are presented as mean ± SEM and analyzed using two-way ANOVA followed by Turkey’s multiple comparisons test. * p < 0.05; ** p < 0.01; *** p < 0.01; **** p < 0.0001 vs. saline group. # p < 0.05. ## p < 0.01; ### p < 0.001 vs. cocaine group; ns, p > 0.05.
Inhibitor Of Ceramide Synthase Myriocin, supplied by Biomol GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/myriocin/inhibitor+of+ceramide+synthase+myriocin/pm17550847-58-5-9
Average 90 stars, based on 1 article reviews
inhibitor of ceramide synthase myriocin - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
myriocin (isp-1) 476300-5mg  (Merck KGaA)
90
Merck KGaA myriocin (isp-1) 476300-5mg
<t>SPT</t> inhibition represses cocaine-induced neurobehaviors and sphingolipid metabolism reprogramming in the NAc. (A) Upper: diagram of establishing cocaine-induced hyperlocomotor activity in mice with <t>myriocin</t> pretreatment. Lower: total distances of mice travelled before or after i.p. injection of 20 mg/kg cocaine with myriocin pretreatment (0.3, 1 mg/kg) and the vehicle control (n = 10). Mice received vehicle or myriocin 30 min before daily behavioral testing. (B) Bar graph shows the changes of SPT activity measured by ELISA assay in mice pretreated with myriocin (1 mg/kg) (n = 6). Main effects: cocaine, F (1,20) = 9.455, p = 0.006; myriocin, F (1,20) = 28.21, p < 0.0001; interaction, F (1,20) = 28.58, p < 0.0001. (C,D) Bar graph shows the levels of 3-ketosphinganine (C) and dihydrosphinganine (D) in the NAc of cocaine-treated mice with myriocin (1 mg/kg) pretreatment (n = 4). 3-ketosphinganine, main effects: cocaine, F (1,12) = 9.455, p = 0.006; myriocin, F (1,12) = 28.21, p < 0.0001; interaction, F (1,12) = 28.58, p < 0.0001. Dihydrosphinganine, main effects: cocaine, F (1,12) = 12.73, p = 0.0039; myriocin, F (1,12) = 5.8529, p = 0.0327; interaction, F (1,12) = 4.175, p = 0.0636. (E) The dot matrix chart shows eight minor categories of sphingolipids significantly changed by myriocin (1 mg/kg) pretreatment in cocaine-treated group. The color of the dots represents a lipid subclass and the quantity of the dots represents the percentage. (F) Bar graph shows the intensity of a series of changed sphingolipids in the NAc of mice with cocaine-induced hyperlocomotion (n = 10). (G) Diagram of establishing cocaine CPP model. Bar graph shows the cocaine CPP scores with myriocin pretreatment and the vehicle control (0.3, 1 mg/kg) (n = 8). (H,I) Bar graph shows the levels of 3-ketosphinganine (H) and dihydrosphinganine (I) in the NAc of cocaine CPP mice with myriocin (1 mg/kg) pretreatment (n = 4). 3-ketosphinganine, main effects: cocaine, F (1,12) = 11.57, p = 0.0052; myriocin, F (1,12) = 15.43, p = 0.0020; interaction, F (1,12) = 6.280, p = 0.0276; Dihydrosphinganine, main effects: cocaine, F (1,12) = 1.456, p = 0.2508; myriocin, F (1,12) = 0.0949, p = 0.7633; interaction, F (1,12) = 5.285, p = 0.0403. (J) The dot matrix chart shows eight minor categories of sphingolipids significantly modified by myriocin (1 mg/kg) of cocaine-treated mice. (K) Bar graph shows the intensity of a series of changed sphingolipids in the NAc of cocaine CPP mice with myriocin (1 mg/kg) pretreatment (n = 10). Data are presented as mean ± SEM and analyzed using two-way ANOVA followed by Turkey’s multiple comparisons test. * p < 0.05; ** p < 0.01; *** p < 0.01; **** p < 0.0001 vs. saline group. # p < 0.05. ## p < 0.01; ### p < 0.001 vs. cocaine group; ns, p > 0.05.
Myriocin (Isp 1) 476300 5mg, supplied by Merck KGaA, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/myriocin/myriocin+476300+5mg/pm32824643-298-0-5
Average 90 stars, based on 1 article reviews
myriocin (isp-1) 476300-5mg - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
myriocin  (Verlag GmbH)
90
Verlag GmbH myriocin
<t>SPT</t> inhibition represses cocaine-induced neurobehaviors and sphingolipid metabolism reprogramming in the NAc. (A) Upper: diagram of establishing cocaine-induced hyperlocomotor activity in mice with <t>myriocin</t> pretreatment. Lower: total distances of mice travelled before or after i.p. injection of 20 mg/kg cocaine with myriocin pretreatment (0.3, 1 mg/kg) and the vehicle control (n = 10). Mice received vehicle or myriocin 30 min before daily behavioral testing. (B) Bar graph shows the changes of SPT activity measured by ELISA assay in mice pretreated with myriocin (1 mg/kg) (n = 6). Main effects: cocaine, F (1,20) = 9.455, p = 0.006; myriocin, F (1,20) = 28.21, p < 0.0001; interaction, F (1,20) = 28.58, p < 0.0001. (C,D) Bar graph shows the levels of 3-ketosphinganine (C) and dihydrosphinganine (D) in the NAc of cocaine-treated mice with myriocin (1 mg/kg) pretreatment (n = 4). 3-ketosphinganine, main effects: cocaine, F (1,12) = 9.455, p = 0.006; myriocin, F (1,12) = 28.21, p < 0.0001; interaction, F (1,12) = 28.58, p < 0.0001. Dihydrosphinganine, main effects: cocaine, F (1,12) = 12.73, p = 0.0039; myriocin, F (1,12) = 5.8529, p = 0.0327; interaction, F (1,12) = 4.175, p = 0.0636. (E) The dot matrix chart shows eight minor categories of sphingolipids significantly changed by myriocin (1 mg/kg) pretreatment in cocaine-treated group. The color of the dots represents a lipid subclass and the quantity of the dots represents the percentage. (F) Bar graph shows the intensity of a series of changed sphingolipids in the NAc of mice with cocaine-induced hyperlocomotion (n = 10). (G) Diagram of establishing cocaine CPP model. Bar graph shows the cocaine CPP scores with myriocin pretreatment and the vehicle control (0.3, 1 mg/kg) (n = 8). (H,I) Bar graph shows the levels of 3-ketosphinganine (H) and dihydrosphinganine (I) in the NAc of cocaine CPP mice with myriocin (1 mg/kg) pretreatment (n = 4). 3-ketosphinganine, main effects: cocaine, F (1,12) = 11.57, p = 0.0052; myriocin, F (1,12) = 15.43, p = 0.0020; interaction, F (1,12) = 6.280, p = 0.0276; Dihydrosphinganine, main effects: cocaine, F (1,12) = 1.456, p = 0.2508; myriocin, F (1,12) = 0.0949, p = 0.7633; interaction, F (1,12) = 5.285, p = 0.0403. (J) The dot matrix chart shows eight minor categories of sphingolipids significantly modified by myriocin (1 mg/kg) of cocaine-treated mice. (K) Bar graph shows the intensity of a series of changed sphingolipids in the NAc of cocaine CPP mice with myriocin (1 mg/kg) pretreatment (n = 10). Data are presented as mean ± SEM and analyzed using two-way ANOVA followed by Turkey’s multiple comparisons test. * p < 0.05; ** p < 0.01; *** p < 0.01; **** p < 0.0001 vs. saline group. # p < 0.05. ## p < 0.01; ### p < 0.001 vs. cocaine group; ns, p > 0.05.
Myriocin, supplied by Verlag GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/myriocin/myriocin/pm20066678-73-0-4
Average 90 stars, based on 1 article reviews
myriocin - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
myriocin  (Enzo Biochem)
90
Enzo Biochem myriocin
<t>SPT</t> inhibition represses cocaine-induced neurobehaviors and sphingolipid metabolism reprogramming in the NAc. (A) Upper: diagram of establishing cocaine-induced hyperlocomotor activity in mice with <t>myriocin</t> pretreatment. Lower: total distances of mice travelled before or after i.p. injection of 20 mg/kg cocaine with myriocin pretreatment (0.3, 1 mg/kg) and the vehicle control (n = 10). Mice received vehicle or myriocin 30 min before daily behavioral testing. (B) Bar graph shows the changes of SPT activity measured by ELISA assay in mice pretreated with myriocin (1 mg/kg) (n = 6). Main effects: cocaine, F (1,20) = 9.455, p = 0.006; myriocin, F (1,20) = 28.21, p < 0.0001; interaction, F (1,20) = 28.58, p < 0.0001. (C,D) Bar graph shows the levels of 3-ketosphinganine (C) and dihydrosphinganine (D) in the NAc of cocaine-treated mice with myriocin (1 mg/kg) pretreatment (n = 4). 3-ketosphinganine, main effects: cocaine, F (1,12) = 9.455, p = 0.006; myriocin, F (1,12) = 28.21, p < 0.0001; interaction, F (1,12) = 28.58, p < 0.0001. Dihydrosphinganine, main effects: cocaine, F (1,12) = 12.73, p = 0.0039; myriocin, F (1,12) = 5.8529, p = 0.0327; interaction, F (1,12) = 4.175, p = 0.0636. (E) The dot matrix chart shows eight minor categories of sphingolipids significantly changed by myriocin (1 mg/kg) pretreatment in cocaine-treated group. The color of the dots represents a lipid subclass and the quantity of the dots represents the percentage. (F) Bar graph shows the intensity of a series of changed sphingolipids in the NAc of mice with cocaine-induced hyperlocomotion (n = 10). (G) Diagram of establishing cocaine CPP model. Bar graph shows the cocaine CPP scores with myriocin pretreatment and the vehicle control (0.3, 1 mg/kg) (n = 8). (H,I) Bar graph shows the levels of 3-ketosphinganine (H) and dihydrosphinganine (I) in the NAc of cocaine CPP mice with myriocin (1 mg/kg) pretreatment (n = 4). 3-ketosphinganine, main effects: cocaine, F (1,12) = 11.57, p = 0.0052; myriocin, F (1,12) = 15.43, p = 0.0020; interaction, F (1,12) = 6.280, p = 0.0276; Dihydrosphinganine, main effects: cocaine, F (1,12) = 1.456, p = 0.2508; myriocin, F (1,12) = 0.0949, p = 0.7633; interaction, F (1,12) = 5.285, p = 0.0403. (J) The dot matrix chart shows eight minor categories of sphingolipids significantly modified by myriocin (1 mg/kg) of cocaine-treated mice. (K) Bar graph shows the intensity of a series of changed sphingolipids in the NAc of cocaine CPP mice with myriocin (1 mg/kg) pretreatment (n = 10). Data are presented as mean ± SEM and analyzed using two-way ANOVA followed by Turkey’s multiple comparisons test. * p < 0.05; ** p < 0.01; *** p < 0.01; **** p < 0.0001 vs. saline group. # p < 0.05. ## p < 0.01; ### p < 0.001 vs. cocaine group; ns, p > 0.05.
Myriocin, supplied by Enzo Biochem, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/myriocin/myriocin/pmc03784522-394-0-1
Average 90 stars, based on 1 article reviews
myriocin - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

Image Search Results


SPT inhibition represses cocaine-induced neurobehaviors and sphingolipid metabolism reprogramming in the NAc. (A) Upper: diagram of establishing cocaine-induced hyperlocomotor activity in mice with myriocin pretreatment. Lower: total distances of mice travelled before or after i.p. injection of 20 mg/kg cocaine with myriocin pretreatment (0.3, 1 mg/kg) and the vehicle control (n = 10). Mice received vehicle or myriocin 30 min before daily behavioral testing. (B) Bar graph shows the changes of SPT activity measured by ELISA assay in mice pretreated with myriocin (1 mg/kg) (n = 6). Main effects: cocaine, F (1,20) = 9.455, p = 0.006; myriocin, F (1,20) = 28.21, p < 0.0001; interaction, F (1,20) = 28.58, p < 0.0001. (C,D) Bar graph shows the levels of 3-ketosphinganine (C) and dihydrosphinganine (D) in the NAc of cocaine-treated mice with myriocin (1 mg/kg) pretreatment (n = 4). 3-ketosphinganine, main effects: cocaine, F (1,12) = 9.455, p = 0.006; myriocin, F (1,12) = 28.21, p < 0.0001; interaction, F (1,12) = 28.58, p < 0.0001. Dihydrosphinganine, main effects: cocaine, F (1,12) = 12.73, p = 0.0039; myriocin, F (1,12) = 5.8529, p = 0.0327; interaction, F (1,12) = 4.175, p = 0.0636. (E) The dot matrix chart shows eight minor categories of sphingolipids significantly changed by myriocin (1 mg/kg) pretreatment in cocaine-treated group. The color of the dots represents a lipid subclass and the quantity of the dots represents the percentage. (F) Bar graph shows the intensity of a series of changed sphingolipids in the NAc of mice with cocaine-induced hyperlocomotion (n = 10). (G) Diagram of establishing cocaine CPP model. Bar graph shows the cocaine CPP scores with myriocin pretreatment and the vehicle control (0.3, 1 mg/kg) (n = 8). (H,I) Bar graph shows the levels of 3-ketosphinganine (H) and dihydrosphinganine (I) in the NAc of cocaine CPP mice with myriocin (1 mg/kg) pretreatment (n = 4). 3-ketosphinganine, main effects: cocaine, F (1,12) = 11.57, p = 0.0052; myriocin, F (1,12) = 15.43, p = 0.0020; interaction, F (1,12) = 6.280, p = 0.0276; Dihydrosphinganine, main effects: cocaine, F (1,12) = 1.456, p = 0.2508; myriocin, F (1,12) = 0.0949, p = 0.7633; interaction, F (1,12) = 5.285, p = 0.0403. (J) The dot matrix chart shows eight minor categories of sphingolipids significantly modified by myriocin (1 mg/kg) of cocaine-treated mice. (K) Bar graph shows the intensity of a series of changed sphingolipids in the NAc of cocaine CPP mice with myriocin (1 mg/kg) pretreatment (n = 10). Data are presented as mean ± SEM and analyzed using two-way ANOVA followed by Turkey’s multiple comparisons test. * p < 0.05; ** p < 0.01; *** p < 0.01; **** p < 0.0001 vs. saline group. # p < 0.05. ## p < 0.01; ### p < 0.001 vs. cocaine group; ns, p > 0.05.

Journal: Frontiers in Pharmacology

Article Title: ER stress in D1-MSNs mediates cocaine-induced behavioral plasticity via the ATF4–SPTLC1 axis

doi: 10.3389/fphar.2025.1677343

Figure Lengend Snippet: SPT inhibition represses cocaine-induced neurobehaviors and sphingolipid metabolism reprogramming in the NAc. (A) Upper: diagram of establishing cocaine-induced hyperlocomotor activity in mice with myriocin pretreatment. Lower: total distances of mice travelled before or after i.p. injection of 20 mg/kg cocaine with myriocin pretreatment (0.3, 1 mg/kg) and the vehicle control (n = 10). Mice received vehicle or myriocin 30 min before daily behavioral testing. (B) Bar graph shows the changes of SPT activity measured by ELISA assay in mice pretreated with myriocin (1 mg/kg) (n = 6). Main effects: cocaine, F (1,20) = 9.455, p = 0.006; myriocin, F (1,20) = 28.21, p < 0.0001; interaction, F (1,20) = 28.58, p < 0.0001. (C,D) Bar graph shows the levels of 3-ketosphinganine (C) and dihydrosphinganine (D) in the NAc of cocaine-treated mice with myriocin (1 mg/kg) pretreatment (n = 4). 3-ketosphinganine, main effects: cocaine, F (1,12) = 9.455, p = 0.006; myriocin, F (1,12) = 28.21, p < 0.0001; interaction, F (1,12) = 28.58, p < 0.0001. Dihydrosphinganine, main effects: cocaine, F (1,12) = 12.73, p = 0.0039; myriocin, F (1,12) = 5.8529, p = 0.0327; interaction, F (1,12) = 4.175, p = 0.0636. (E) The dot matrix chart shows eight minor categories of sphingolipids significantly changed by myriocin (1 mg/kg) pretreatment in cocaine-treated group. The color of the dots represents a lipid subclass and the quantity of the dots represents the percentage. (F) Bar graph shows the intensity of a series of changed sphingolipids in the NAc of mice with cocaine-induced hyperlocomotion (n = 10). (G) Diagram of establishing cocaine CPP model. Bar graph shows the cocaine CPP scores with myriocin pretreatment and the vehicle control (0.3, 1 mg/kg) (n = 8). (H,I) Bar graph shows the levels of 3-ketosphinganine (H) and dihydrosphinganine (I) in the NAc of cocaine CPP mice with myriocin (1 mg/kg) pretreatment (n = 4). 3-ketosphinganine, main effects: cocaine, F (1,12) = 11.57, p = 0.0052; myriocin, F (1,12) = 15.43, p = 0.0020; interaction, F (1,12) = 6.280, p = 0.0276; Dihydrosphinganine, main effects: cocaine, F (1,12) = 1.456, p = 0.2508; myriocin, F (1,12) = 0.0949, p = 0.7633; interaction, F (1,12) = 5.285, p = 0.0403. (J) The dot matrix chart shows eight minor categories of sphingolipids significantly modified by myriocin (1 mg/kg) of cocaine-treated mice. (K) Bar graph shows the intensity of a series of changed sphingolipids in the NAc of cocaine CPP mice with myriocin (1 mg/kg) pretreatment (n = 10). Data are presented as mean ± SEM and analyzed using two-way ANOVA followed by Turkey’s multiple comparisons test. * p < 0.05; ** p < 0.01; *** p < 0.01; **** p < 0.0001 vs. saline group. # p < 0.05. ## p < 0.01; ### p < 0.001 vs. cocaine group; ns, p > 0.05.

Article Snippet: The SPT antagonist, myriocin (#HY-N6798, Med Chem Express) was dissolved in saline containing 5% (V/V) DMSO to a final concentration of 10 mg/mL as a stock.

Techniques: Inhibition, Activity Assay, Injection, Control, Enzyme-linked Immunosorbent Assay, Modification, Saline